XTX Topco Ltd Invests $261,000 in STERIS plc (NYSE:STE)

XTX Topco Ltd purchased a new stake in shares of STERIS plc (NYSE:STE - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,272 shares of the medical equipment provider's stock, valued at approximately $261,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of STE. Avalon Trust Co bought a new stake in shares of STERIS during the 4th quarter worth $30,000. Human Investing LLC purchased a new position in STERIS in the 4th quarter worth about $31,000. Anfield Capital Management LLC increased its stake in STERIS by 100.0% in the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 91 shares in the last quarter. Central Pacific Bank Trust Division lifted its stake in STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 76 shares in the last quarter. Finally, Manchester Capital Management LLC boosted its holdings in shares of STERIS by 182.7% in the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock worth $44,000 after buying an additional 137 shares during the period. Institutional investors own 94.69% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC restated a "hold" rating on shares of STERIS in a report on Monday, April 7th. JMP Securities restated a "market outperform" rating and issued a $265.00 target price on shares of STERIS in a report on Thursday, April 10th. Stephens reaffirmed an "overweight" rating and issued a $240.00 target price on shares of STERIS in a research report on Thursday, February 6th. Finally, Piper Sandler upped their price target on STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $258.75.

STERIS Stock Down 0.9 %

Shares of NYSE STE traded down $2.09 during mid-day trading on Thursday, reaching $222.65. The company had a trading volume of 329,261 shares, compared to its average volume of 533,296. The stock has a market capitalization of $21.88 billion, a PE ratio of 47.33 and a beta of 0.87. STERIS plc has a twelve month low of $200.98 and a twelve month high of $248.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13. The stock's 50 day moving average is $223.12 and its 200-day moving average is $218.91.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. As a group, equities analysts anticipate that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.